Overview

A textbook example of what targeted peptide engineering achieves. Two deliberate modifications to vasopressin removed the blood-pressure effect, kept the water-retention effect, and extended the duration — turning a pressor into a safe outpatient medicine with an unexpected second career in bleeding disorders.

FDA ApprovedFDA-approved for central diabetes insipidus, primary nocturnal enuresis, nocturia, and for bleeding in mild haemophilia A and von Willebrand disease type 1.

At a glance

Regulatory status	FDA-approved for central diabetes insipidus, primary nocturnal enuresis, nocturia, and for bleeding in mild haemophilia A and von Willebrand disease type 1.
Drug class	Synthetic vasopressin analog — nonapeptide selective for the V2 receptor
Route	Oral, intranasal, intravenous or subcutaneous
Half-life	~3 hours (biological effect considerably longer)
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong Multiple phase 3 randomized trials plus regulatory approval in a major market.
Studied in	Decades of trials across diabetes insipidus, nocturia, enuresis, and haemostatic use in mild haemophilia A and von Willebrand disease.

How it works

Selective V2 receptor agonism in the renal collecting duct inserts aquaporin-2 channels, concentrating urine. Deamination at position 1 and D-arginine substitution at position 8 remove V1-mediated vasoconstriction and slow degradation. V2 stimulation on endothelium also releases stored von Willebrand factor and factor VIII, which is the basis of the haemostatic indication.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

Decades of trials across several distinct indications, each with its own evidence base and its own risk profile.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Definitive therapy for central diabetes insipidus Strong evidence

Replaces the missing hormone directly, controlling polyuria and polydipsia — the clearest indication.
Releases von Willebrand factor and factor VIII Strong evidence

Raises levels several-fold within an hour, often avoiding blood product exposure for minor procedures in mild disease.
Reduces nocturia and nocturnal enuresis Strong evidence

Established efficacy with dedicated formulations and sex-specific dosing for nocturia.
No pressor effect Strong evidence

The V1 selectivity engineered out means it does not raise blood pressure the way vasopressin does.
Multiple routes available Strong evidence

Oral, sublingual, intranasal and injectable, allowing the route to match the indication.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Hyponatremia — the central risk Serious

Water retention without solute causes dilutional hyponatremia, which can progress to seizures and death. This has caused deaths in nocturia and enuresis treatment, and drove a boxed warning on some formulations.
Fluid restriction is mandatory, not advisory Serious

Patients must limit fluid intake around dosing. Failure to do so is the usual route to severe hyponatremia.
Elderly patients are markedly higher risk Serious

Age-related reduction in free water clearance makes hyponatremia both more likely and more dangerous; some formulations are not recommended over 65.
Tachyphylaxis in haemostatic use Moderate evidence

Stored von Willebrand factor is depleted after repeated doses, so the haemostatic effect fades within 2–3 doses.
Thrombotic events reported Moderate evidence

Rare arterial thrombotic events have been reported with haemostatic use in patients with cardiovascular risk.
Ineffective in nephrogenic diabetes insipidus Moderate evidence

The defect is receptor-level, so supplying more hormone does nothing.
Nasal formulation variability Moderate evidence

Absorption varies with rhinitis and technique; some nasal products were withdrawn over dosing inconsistency.

Who should avoid it

Hyponatremia or history of hyponatremia
Moderate to severe renal impairment
SIADH
Uncontrolled heart failure
Polydipsia
Concurrent loop diuretics or SSRIs (relative — both raise hyponatremia risk)

If used under medical supervision, monitor

Serum sodium before starting, within the first week, then periodically — non-negotiable in older adults
Fluid intake around dosing
Weight and oedema
Factor VIII and von Willebrand factor levels for haemostatic use

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

SSRIs, tricyclics, carbamazepine, chlorpropamide — all increase hyponatremia risk
NSAIDs — increase antidiuretic effect and hyponatremia risk
Loop diuretics — compound sodium disturbance
Glucocorticoids — reduce effect

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Oxytocin FDA Approved Evidence 5/5

Oxytocin and vasopressin differ by only two amino acids, which is why high-dose oxytocin causes water retention and hyponatremia. Desmopressin is the engineered vasopressin analog; the two are not interchangeable.

Compare side by side

Regulatory & legal status

Prescription drug across all formulations.

Infographic

Desmopressin — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

diabetes insipidusbleeding disordersnocturiavasopressinapproved

Related peptides in Cardiac & Vascular

Terms used on this page

Vasopressin: Vasopressin is a nine-amino-acid posterior pituitary hormone that conserves water through renal V2 receptors and constricts vasculature through V1a receptors, released in response to plasma osmolality.
D-Amino Acid Substitution: D-amino acid substitution replaces a natural L residue with its mirror image to break protease recognition at that position, greatly extending an analogue's duration of action.
Agonist: An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
Receptor Selectivity: Receptor selectivity is the degree to which a ligand acts on its intended receptor rather than related ones, expressed as the ratio between its potency at the target and at each off-target.
Intranasal Delivery: Intranasal delivery uses the nasal mucosa as an absorption surface, offering needle-free administration and rapid onset but low and variable bioavailability for peptides.
Sublingual and Buccal Delivery: Sublingual and buccal delivery route a drug across the mucosa lining the floor of the mouth or the cheek, entering the circulation directly and bypassing gastric acid and hepatic first pass.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.